Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

BJU International, 05/04/2012

Serenoa repens therapy does not improve lower urinary tract symptoms or maximum urinary flow rate compared with placebo in men with benign prostatic hyperplasia, even at double and triple the usual dose. Adverse events were generally mild and comparable to placebo.

Print Article Summary Cat 2 CME Report